Top Story

Question your allocation to deal with recent stock market volatility

October 30, 2014

The summer stock market doldrums have morphed into a high octane volatile zig-zag. So I ask you – what is new? Haven’t we been here before? The trouble is that we just haven’t had a serious market correction since July-August 2011 and many moons before that. We have forgotten that markets go down and up, but deep in the recesses of our minds, we remember the pain of the deep market decline of 2008-2009. That is why recent headlines have scared us.

Readers who have followed my articles over the years may recall my comments about “the big mistake.” It is the sudden, emotional unobjective reaction to unexpected market volatility and the knee-jerk decision to sell into a down market thus turning a decline into a loss. It is a naturally human “buy-high, sell-low” pattern that unfortunately repeats itself in the minds of many investors.

Meeting News Coverage

Antimicrobials, herbal and dietary supplements common causes of idiosyncratic DILI

October 30, 2014
PHILADELPHIA — Antimicrobials and herbal and dietary supplements are the most common causes of idiosyncratic drug-induced liver injury, or DILI, according to data…
In the Journals

Clustering prevalent among injection drug users with HCV in Vancouver

October 30, 2014
One-third of people who inject drugs with hepatitis C virus infection from the Vancouver Injection Drug Users Study were found to be clustered, a phenomenon that is a…
FDA News

FDA approves clinical trial for potential HCC chemotherapy drug

October 30, 2014
The FDA approved the initiation of an investigational device exemption clinical trial of a potential chemotherapy drug, Oncozene, for the treatment of hepatocellular…
More News Headlines »
CME
figure

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
Meeting News Coverage Video
figure

Marshall discusses the safety, efficacy of a potential combination vaccine for infants

October 28, 2014
PHILADELPHIA — At IDWeek 2014, Gary S. Marshall, MD, chief of pediatric infectious diseases at the University of…
More »
CME
figure

HCV Consults: Volume 1, Number 2

This activity is supported by educational grants from AbbVie and Genentech.

Approved interferon-free therapy has already become entrenched among clinicians for patients with HCV genotypes 2 and…
More »